

【Therapeutic category】 429 Other antitumor agents

【Non-proprietary name】 Avelumab (genetical recombination)

Ipilimumab (genetical recombination)

Tislelizumab (genetical recombination)

Durvalumab (genetical recombination)

Tremelimumab (genetical recombination)

Retifanlimab (genetical recombination)

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions N/A	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Haemophagocytic lymphohistiocytosis</u>

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.